Gland Pharma Q2 FY27: Profit Jumps 58% to ₹291 Crore

Gland Pharma ( GLAND ) delivered a strong Q2 FY27 performance, with revenue growing 23% and net profit rising 58% year-on-year. Strong growth in its CDMO business, improving margins and new product launches in the US supported the performance. Key Q2 FY27 Highlights - Revenue: ₹1,834 crore, up 23% YoY. - Net profit: ₹290.8 crore, up 58% YoY. - EBITDA: ₹480.4 crore, up 53% YoY. - Adjusted EBITDA margin: Expanded to 27% from 23%. - CDMO business: Contributed 45% of revenue and grew 31%. - Critical Injectables: Contributed 55% of revenue, growing 18%. - R&D expenditure: ₹107.7 crore, around 6% of revenue. What Is Driving the Growth? The CDMO business is emerging as an important growth driver, supported by new customer engagements, strategic partnerships and global outsourcing opportunities. Gland Pharma also launched four molecules in the US during the quarter and filed 11 ANDAs, receiving 10 approvals. Its cumulative US ANDA approvals have reached 350. My View Gland Pharma's results are encouraging because profit growth is accompanied by strong revenue expansion and margin improvement. The 31% growth in CDMO is particularly important as it strengthens the company's long-term growth opportunity. However, investors should monitor the sustainability of US market growth, regulatory approvals, R&D productivity and the company's ability to maintain margins. One point to note: net profit declined 8% sequentially compared with Q1 FY27, despite strong year-on-year growth. This makes quarterly execution equally important to track. In my view, Gland Pharma's growth story is strengthening, but consistent execution and earnings visibility will determine whether the momentum can sustain.